Results 181 to 190 of about 926,237 (299)

Burkholderia cepacia complex in septicaemic non-cystic fibrosis cases from two tertiary care hospitals in north India [PDF]

open access: yes, 2010
Arora, Anita   +12 more
core   +2 more sources

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman   +9 more
wiley   +1 more source

Editorial: Advances in infectious disease research: tackling antimicrobial resistance, zoonoses, and more

open access: yesFrontiers in Cellular and Infection Microbiology
Priyanka Bhoj   +4 more
doaj   +1 more source

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single‐centre study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga   +20 more
wiley   +1 more source

Predictors for Publication of Specialty Theses in the Field of Infectious Diseases and Clinical Microbiology. [PDF]

open access: yesInfect Dis Clin Microbiol
İrkören P   +22 more
europepmc   +1 more source

CLINICAL MICROBIOLOGY REVIEWS [PDF]

open access: yesClinical Microbiology Reviews, 2007
openaire   +1 more source

RBD‐SD1 Nanoparticle Vaccines From DPP4‐Using Merbecoviruses Elicit a Cross‐Reactive Antibody Response but Limited Cross‐Protective Immunity

open access: yesBiotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles displaying RBD‐SD1 from MERS‐CoV, NL140422, and HKU4 elicited robust and cross‐reactive IgG responses in mice. Only MERS‐CoV RBD‐SD1 induced neutralizing antibodies against MERS‐CoV and protected human DPP4 mice from a MERS‐CoV challenge, indicating conserved serologic but limited cross‐neutralizing epitopes.
Peter J. Halfmann   +9 more
wiley   +1 more source

Barriers and perceptions of WHONET/BacLink adoption in Nepal: A qualitative study of clinical microbiology laboratories. [PDF]

open access: yesPLoS One
Maharjan S   +17 more
europepmc   +1 more source

A thorn injury, a sea‐borne culprit, and a tenosynovitis dilemma

open access: yes
Arthritis &Rheumatology, Accepted Article.
Jacopo Ciaffi   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy